August 9, 2016 / 10:17 PM / a year ago

BRIEF-Immunovaccine names Frederic Ors permanent CEO

Aug 9 (Reuters) - Immunovaccine Inc

* Immunovaccine provides corporate update and announces second quarter 2016 financial results

* Says securing $8 million in a bought deal private placement financing

* Immunovaccine Inc says appointing Medicago CEO and president Andy Sheldon as board chairman, and CTI LSF’s Shermaine Tilley as a board director

* Says “ceasing our Pharmathene collaboration related to anthrax”

* Says naming Frederic Ors permanent chief executive officer

* Says initiating a search for a chief medical officer

* Qtrly net loss and comprehensive loss of $1.4 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below